These results have led to approval of palbociclib in early 2015 by the Food and Drug Administration (FDA) for the treatment of postmenopausal women with ER-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. Here, ESR1 is linked to breast cancer.